351 related articles for article (PubMed ID: 18957950)
1. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?
Wetmore JB; Quarles LD
Nat Clin Pract Nephrol; 2009 Jan; 5(1):24-33. PubMed ID: 18957950
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
4. [Frontiers in vitamin D; basic research and clinical application. Vitamin D and secondary hyperparathyroidism].
Tanaka H; Komaba H; Fukagawa M
Clin Calcium; 2011 Nov; 21(11):27-34. PubMed ID: 22040818
[TBL] [Abstract][Full Text] [Related]
5. Management of mineral and bone disorder in chronic kidney disease: quo vadis?
Nakai K; Komaba H; Fukagawa M
Ther Apher Dial; 2009 Oct; 13 Suppl 1():S2-6. PubMed ID: 19765254
[TBL] [Abstract][Full Text] [Related]
6. Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.
Wetmore JB; Quarles LD
Int J Nephrol Renovasc Dis; 2008; 1():5-17. PubMed ID: 21694914
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.
Quarles LD
Kidney Int Suppl; 2005 Jul; (96):S24-8. PubMed ID: 15954947
[TBL] [Abstract][Full Text] [Related]
8. Calcimimetics in chronic kidney disease: evidence, opportunities and challenges.
Evenepoel P
Kidney Int; 2008 Aug; 74(3):265-75. PubMed ID: 18528328
[TBL] [Abstract][Full Text] [Related]
9. New approaches to treatment of secondary hyperparathyroidism.
Locatelli F; Limardo M; Pontoriero G
Curr Opin Investig Drugs; 2008 Apr; 9(4):363-70. PubMed ID: 18393103
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.
Brancaccio D; Bommer J; Coyne D
Drugs; 2007; 67(14):1981-98. PubMed ID: 17883283
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic strategies for secondary hyperparathyroidism in dialysis patients.
Ogata H; Koiwa F; Ito H; Kinugasa E
Ther Apher Dial; 2006 Aug; 10(4):355-63. PubMed ID: 16911189
[TBL] [Abstract][Full Text] [Related]
13. Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease.
Cozzolino M; Gallieni M; Pasho S; Fallabrino G; Ciceri P; Volpi EM; Olivi L; Brancaccio D
Drugs Aging; 2009; 26(6):457-68. PubMed ID: 19591520
[TBL] [Abstract][Full Text] [Related]
14. Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivatives.
Drüeke TB; Ritz E
Clin J Am Soc Nephrol; 2009 Jan; 4(1):234-41. PubMed ID: 19056615
[TBL] [Abstract][Full Text] [Related]
15. Secondary Hyperparathyroidism: Pathogenesis and Latest Treatment.
Mizobuchi M; Ogata H; Koiwa F
Ther Apher Dial; 2019 Aug; 23(4):309-318. PubMed ID: 30411503
[TBL] [Abstract][Full Text] [Related]
16. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
Hudson JQ
Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
[TBL] [Abstract][Full Text] [Related]
17. [Parathyroid and bone. Calcimimetics and bone metabolism].
Fukumoto S
Clin Calcium; 2007 Dec; 17(12):1865-9. PubMed ID: 18057662
[TBL] [Abstract][Full Text] [Related]
18. [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
Akiba T
Clin Calcium; 2007 May; 17(5):767-71. PubMed ID: 17471008
[TBL] [Abstract][Full Text] [Related]
19. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for secondary hyperparathyroidism.
Cozzolino M; Tomlinson J; Walsh L; Bellasi A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):197-208. PubMed ID: 25702624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]